Russia’s sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy’s Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
- Turkey signs 50 million dose COVID-19 vaccine deal, health minister says
- Coronavirus: WHO sees progressive control of COVID-19 in 2021, cautions on Christmas
- Coronavirus: UAE officials expect vaccine to be available by end of 2020, early 2021
- Coronavirus: Five COVID-19 patients killed in India hospital fire